Last reviewed · How we verify

NCT04917016

B-HCG Levels in Women Diagnosed With Retained Products of Conception

Completed Last updated 8 June 2021
What this trial tests

trial testing Plasma B-HCG levels in Retained Products of Conception in 200 participants. Completed in 28 February 2021.

Timeline
1 December 2019
Primary endpoint
28 February 2021
28 February 2021

Quick facts

Lead sponsorAssaf-Harofeh Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 December 2019
Primary completion28 February 2021
Estimated completion28 February 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Assaf-Harofeh Medical Center

Who can join

Adults 18 to 45, female only, with Retained Products of Conception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retained Products of Conception (RPOC) is a condition where gestational tissue remains in the uterus after birth or after a surgical or medical abortion. This condition may cause significant bleeding, infection, and long-term intrauterine adhesions associated with fertility problems and pregnancy complications (Asherman's syndrome). RPOC are diagnosed according to the clinical and ultrasound findings (such as an echogenic foci in the uterine cavity with Doppler blood flows). However, the diagnosis of RPOC by clinic and ultrasound characteristics is inaccurate and false positive results are reported in up to 40% of women undergoing a surgical procedure for RPOC removal (most often by hysterosocpy). However, surgery also carries a risk of complications and intrauterine infections. Therefore, the need arises for additional tools to improve the diagnosis available today in order to minimize the need for surgical procedures as much as possible. The production and secretion of the B-HCG occurs in the placenta and begins after blastocyst implantation. The B-HCG levels increase in other placental pathologies such as gestational trophoblastic disease (GTD). Accordingly, the investigators hypothesized that in cases of placental remnants a secretion of B-HCG may be detected and quantified. In this prospective, non-interventional study the investigators' aim is to examine whether B-HCG can be used as a marker for detecting placental remnants, compared to the currently accepted sonographic method. For this purpose, the investigators will examine the levels of B-HCG in participants undergoing hysteroscopy for removal of RPOC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Retained Products of Conception

Currently open trials in the same condition.

Other Assaf-Harofeh Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04917016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing